p53 Nuclear protein overexpression in colorectal cancer: A dominant predictor of survival in patients with advanced hepatic metastases

C. Belluco, J. G. Guillem, N. Kemeny, Y. Huang, D. Klimstra, M. F. Berger, A. M. Cohen

Research output: Contribution to journalArticle

Abstract

Purpose: To determine whether p53 protein expression is similar within primary colorectal cancer (CRC) and synchronous regional and distant metastases and to assess whether p53 nuclear protein expression could predict outcome in patients with synchronous unresectable liver metastases treated by hepatic artery infusional (HAI) chemotherapy. Materials and Methods: Paraffin sections from tumor and corresponding normal mucosa representative of 50 consecutive advanced CRC cases were examined for p53 nuclear protein expression by immunohistochemistry using the monoclonal antibody PAb 1801. Patterns of p53 nuclear expression were correlated with standard clinicopathologic variables and outcome, including response to HAl and survival. In a subset analysis, the pattern of nuclear p53 immunoreactivity was compared between primary CRC and lymph node and liver metastases. Results: Positive nuclear immunoreactivity for p53 protein was found in 72% of cases. The pattern of p53 protein expression in lymph node and liver metastases was identical to that of the primary tumor. The median survival time was 21.0 months in patients with p53-positive tumors and 53.2 months in patients with p53-negative tumors (Wilcoxon test P = .038). Two-year survival rates were 41.7% and 78.6%, respectively (P <.01). No significant difference was found in the response rates to HAI chemotherapy between the two groups. By multivariate analysis, p53 protein status was the single best predictor of survival, with a relative risk of 6.312. Conclusion: Our results indicate that nuclear p53 protein status in primary CRC is similar to that in metastatic sites and may be the dominant predictor of survival in patients with advanced hepatic metastases.

Original languageEnglish
Pages (from-to)2696-2701
Number of pages6
JournalJournal of Clinical Oncology
Volume14
Issue number10
Publication statusPublished - 1996

Fingerprint

Nuclear Proteins
Colorectal Neoplasms
Neoplasm Metastasis
Survival
Liver
Hepatic Artery
Neoplasms
Proteins
Lymph Nodes
Drug Therapy
Paraffin
Mucous Membrane
Multivariate Analysis
Survival Rate
Immunohistochemistry
Monoclonal Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Belluco, C., Guillem, J. G., Kemeny, N., Huang, Y., Klimstra, D., Berger, M. F., & Cohen, A. M. (1996). p53 Nuclear protein overexpression in colorectal cancer: A dominant predictor of survival in patients with advanced hepatic metastases. Journal of Clinical Oncology, 14(10), 2696-2701.

p53 Nuclear protein overexpression in colorectal cancer : A dominant predictor of survival in patients with advanced hepatic metastases. / Belluco, C.; Guillem, J. G.; Kemeny, N.; Huang, Y.; Klimstra, D.; Berger, M. F.; Cohen, A. M.

In: Journal of Clinical Oncology, Vol. 14, No. 10, 1996, p. 2696-2701.

Research output: Contribution to journalArticle

Belluco, C, Guillem, JG, Kemeny, N, Huang, Y, Klimstra, D, Berger, MF & Cohen, AM 1996, 'p53 Nuclear protein overexpression in colorectal cancer: A dominant predictor of survival in patients with advanced hepatic metastases', Journal of Clinical Oncology, vol. 14, no. 10, pp. 2696-2701.
Belluco, C. ; Guillem, J. G. ; Kemeny, N. ; Huang, Y. ; Klimstra, D. ; Berger, M. F. ; Cohen, A. M. / p53 Nuclear protein overexpression in colorectal cancer : A dominant predictor of survival in patients with advanced hepatic metastases. In: Journal of Clinical Oncology. 1996 ; Vol. 14, No. 10. pp. 2696-2701.
@article{61113ebfa6a04bb299d275dd0cef1f2c,
title = "p53 Nuclear protein overexpression in colorectal cancer: A dominant predictor of survival in patients with advanced hepatic metastases",
abstract = "Purpose: To determine whether p53 protein expression is similar within primary colorectal cancer (CRC) and synchronous regional and distant metastases and to assess whether p53 nuclear protein expression could predict outcome in patients with synchronous unresectable liver metastases treated by hepatic artery infusional (HAI) chemotherapy. Materials and Methods: Paraffin sections from tumor and corresponding normal mucosa representative of 50 consecutive advanced CRC cases were examined for p53 nuclear protein expression by immunohistochemistry using the monoclonal antibody PAb 1801. Patterns of p53 nuclear expression were correlated with standard clinicopathologic variables and outcome, including response to HAl and survival. In a subset analysis, the pattern of nuclear p53 immunoreactivity was compared between primary CRC and lymph node and liver metastases. Results: Positive nuclear immunoreactivity for p53 protein was found in 72{\%} of cases. The pattern of p53 protein expression in lymph node and liver metastases was identical to that of the primary tumor. The median survival time was 21.0 months in patients with p53-positive tumors and 53.2 months in patients with p53-negative tumors (Wilcoxon test P = .038). Two-year survival rates were 41.7{\%} and 78.6{\%}, respectively (P <.01). No significant difference was found in the response rates to HAI chemotherapy between the two groups. By multivariate analysis, p53 protein status was the single best predictor of survival, with a relative risk of 6.312. Conclusion: Our results indicate that nuclear p53 protein status in primary CRC is similar to that in metastatic sites and may be the dominant predictor of survival in patients with advanced hepatic metastases.",
author = "C. Belluco and Guillem, {J. G.} and N. Kemeny and Y. Huang and D. Klimstra and Berger, {M. F.} and Cohen, {A. M.}",
year = "1996",
language = "English",
volume = "14",
pages = "2696--2701",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - p53 Nuclear protein overexpression in colorectal cancer

T2 - A dominant predictor of survival in patients with advanced hepatic metastases

AU - Belluco, C.

AU - Guillem, J. G.

AU - Kemeny, N.

AU - Huang, Y.

AU - Klimstra, D.

AU - Berger, M. F.

AU - Cohen, A. M.

PY - 1996

Y1 - 1996

N2 - Purpose: To determine whether p53 protein expression is similar within primary colorectal cancer (CRC) and synchronous regional and distant metastases and to assess whether p53 nuclear protein expression could predict outcome in patients with synchronous unresectable liver metastases treated by hepatic artery infusional (HAI) chemotherapy. Materials and Methods: Paraffin sections from tumor and corresponding normal mucosa representative of 50 consecutive advanced CRC cases were examined for p53 nuclear protein expression by immunohistochemistry using the monoclonal antibody PAb 1801. Patterns of p53 nuclear expression were correlated with standard clinicopathologic variables and outcome, including response to HAl and survival. In a subset analysis, the pattern of nuclear p53 immunoreactivity was compared between primary CRC and lymph node and liver metastases. Results: Positive nuclear immunoreactivity for p53 protein was found in 72% of cases. The pattern of p53 protein expression in lymph node and liver metastases was identical to that of the primary tumor. The median survival time was 21.0 months in patients with p53-positive tumors and 53.2 months in patients with p53-negative tumors (Wilcoxon test P = .038). Two-year survival rates were 41.7% and 78.6%, respectively (P <.01). No significant difference was found in the response rates to HAI chemotherapy between the two groups. By multivariate analysis, p53 protein status was the single best predictor of survival, with a relative risk of 6.312. Conclusion: Our results indicate that nuclear p53 protein status in primary CRC is similar to that in metastatic sites and may be the dominant predictor of survival in patients with advanced hepatic metastases.

AB - Purpose: To determine whether p53 protein expression is similar within primary colorectal cancer (CRC) and synchronous regional and distant metastases and to assess whether p53 nuclear protein expression could predict outcome in patients with synchronous unresectable liver metastases treated by hepatic artery infusional (HAI) chemotherapy. Materials and Methods: Paraffin sections from tumor and corresponding normal mucosa representative of 50 consecutive advanced CRC cases were examined for p53 nuclear protein expression by immunohistochemistry using the monoclonal antibody PAb 1801. Patterns of p53 nuclear expression were correlated with standard clinicopathologic variables and outcome, including response to HAl and survival. In a subset analysis, the pattern of nuclear p53 immunoreactivity was compared between primary CRC and lymph node and liver metastases. Results: Positive nuclear immunoreactivity for p53 protein was found in 72% of cases. The pattern of p53 protein expression in lymph node and liver metastases was identical to that of the primary tumor. The median survival time was 21.0 months in patients with p53-positive tumors and 53.2 months in patients with p53-negative tumors (Wilcoxon test P = .038). Two-year survival rates were 41.7% and 78.6%, respectively (P <.01). No significant difference was found in the response rates to HAI chemotherapy between the two groups. By multivariate analysis, p53 protein status was the single best predictor of survival, with a relative risk of 6.312. Conclusion: Our results indicate that nuclear p53 protein status in primary CRC is similar to that in metastatic sites and may be the dominant predictor of survival in patients with advanced hepatic metastases.

UR - http://www.scopus.com/inward/record.url?scp=0029738119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029738119&partnerID=8YFLogxK

M3 - Article

C2 - 8874329

AN - SCOPUS:0029738119

VL - 14

SP - 2696

EP - 2701

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -